ChinaCureLinkSep 46 min readAdvancesB-cell lymphoma CAR-T therapy China: BRL-201 for B-Cell Non-Hodgkin Lymphoma — 2026 International Patient Guide
ChinaCureLinkSep 17 min readCasesUnder 10% Odds: How CAR-T Achieved Complete Remission for a 70-Year-Old Lymphoma Patient in China
ChinaCureLinkSep 15 min readCases28 Days: How Dual-Target CAR-T Turned Around a Critical Lymphoma Case for an Egyptian Patient in China
ChinaCureLinkAug 2111 min readBlogBest Lymphoma Hospitals in China: Top Centers, CAR-T Access & 2026 Costs
ChinaCureLinkAug 2112 min readBlog5 Best Lymphoma Hospitals in Asia: Top Centers, CAR-T Access & 2026 Cost Comparison
ChinaCureLinkAug 59 min readCasesCase Study: Twice-Relapsed Lymphoma, One CAR-T Infusion, and a 60-Day Watch That Ended in Remission
ChinaCureLinkJul 297 min readCasesCase Study: Wheelchair-Bound With Bone-Wide Lymphoma, She Was Cancer-Free on PET/CT One Month After CAR-T Therapy at a Shanghai Hospital
ChinaCureLinkJul 18 min readCasesCAR-T Treatment in China for Rare Intestinal T-Cell Lymphoma (MEITL): A Case Study
ChinaCureLinkJun 2312 min readBlog2026 Breakthrough: China's CAR-T for Advanced Lymphoma Reaches 79%+ Response Rate
ChinaCureLinkJun 2210 min readCasesDual-Target CAR-T Cell Therapy for Refractory and Relapsed Burkitt Lymphoma: A Five-Year Survival Case Study in China
ChinaCureLinkMay 206 min readBlogCAR-T Therapy Cost in China for Lymphoma (2026 Guide for International Patients)
